... and its impact on treatment outcomes have not been systematically reviewed. In the present meta-analysis, we aimed to investigate this effect in breast cancer patients since multiple studies have been conducted in this setting. We systematically searched MEDLINE and Cochrane Library up to May 2012...

...G. Pizzolo; A. Molino; R. Sabbioni; G.L. Cetto; A. Iannucci; M. Chilosi Acute lymphoblastic leukaemia, defined by immunological markers as a non-T, non-B, which occurred in a patient with breast cancer 2 years after the end of radiotherapy and CMF adjuvant chemotherapy, is reported. 28 07...

...Axel R. Zander; Nicolaus Kröger The role of high-dose chemotherapy in breast cancer is still controversial despite 20 years of clinical studies. Several nonrandomized studies had demonstrated improvement for patients with primary breast cancer. This led to the premature acceptance of high-dose...

...Christian Chabannon; Sylvain Olivero; Frédéric Viret; Christine Arnoulet; Danielle Sainty; Dominique Maraninchi; Patrice Viens Breast cancer is the most frequent neoplastic disease in populations of developed countries. It will affect 1 of every 6 or 7 women during their lifetime. The disease...

... the influence of clinical and cellular parameters on dose intensity received in a series of 53 patients with metastatic breast cancer or advanced ovarian cancer. They received courses of cisplatin 120 mg/m 2 plus etoposide 600 mg/m 2 alternating every 14 days with ifosfamide 8 g/m 2 plus paclitaxel 200–350 mg/m...

...) containing the p53 tumor suppressor gene (Adv-p53) has been suggested to reduce tumor contamination of autologous stem cell product. We demonstrate herein a safe and effective Adv-p53 purging procedure using four human breast cancer TC lines. Multiple parameters need to be achieved to successfully purge stem...